Current pharmacotherapy options for conduct disorders in adolescents and children

Sohil Khan, John Down, Nisreen Aouira, William Bor, Alison Haywood, Robyn Littlewood, Helen Heussler, Brett McDermott

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Conduct disorder (CD) is a common mental health disorder of childhood and adolescence. CD’s complexity, with its heterogenous clinical manifestations and overlapping comorbidities makes the application of evidence-based management approaches challenging. This article aims to combine a systematic review of the available literature, with a consensus opinion from both child and adolescent psychiatrists and developmental pediatricians on the clinical and pharmacological management of children and adolescents with conduct disorder (CD). Areas covered: The authors review the CD population and provide a systematic review and meta-analysis of the effectiveness and safety of pharmacotherapies using preferred reporting items for systematic review and meta-analysis (PRISMA) and strength of evidence recommendation taxonomy (SORT) guidelines. The authors then provide an expert clinical opinion for the use of different pharmacotherapies to address aggressive and disruptive behavior in children. Expert opinion: Atypical antipsychotics (e.g. risperidone) demonstrate evidence for efficacy in CD. Other pharmacotherapies (e.g. mood stabilizers, anticonvulsants, psychostimulants and selective norepinephrine reuptake inhibitors) have a low level of evidence for CD alone, however, can sometimes be effective in managing the symptoms of CD when other psychiatric disorders are also present.

Original languageEnglish
Pages (from-to)571-583
Number of pages13
JournalExpert Opinion on Pharmacotherapy
Volume20
Issue number5
DOIs
Publication statusPublished - 24-03-2019
Externally publishedYes

Fingerprint

Conduct Disorder
Drug Therapy
Expert Testimony
Psychiatry
Meta-Analysis
Risperidone
Mental Disorders
Anticonvulsants
Antipsychotic Agents
Comorbidity
Consensus
Norepinephrine
Mental Health
Pharmacology
Guidelines
Safety
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Khan, S., Down, J., Aouira, N., Bor, W., Haywood, A., Littlewood, R., ... McDermott, B. (2019). Current pharmacotherapy options for conduct disorders in adolescents and children. Expert Opinion on Pharmacotherapy, 20(5), 571-583. https://doi.org/10.1080/14656566.2018.1561862
Khan, Sohil ; Down, John ; Aouira, Nisreen ; Bor, William ; Haywood, Alison ; Littlewood, Robyn ; Heussler, Helen ; McDermott, Brett. / Current pharmacotherapy options for conduct disorders in adolescents and children. In: Expert Opinion on Pharmacotherapy. 2019 ; Vol. 20, No. 5. pp. 571-583.
@article{e423038b03074ce68c1c626dbc78680d,
title = "Current pharmacotherapy options for conduct disorders in adolescents and children",
abstract = "Introduction: Conduct disorder (CD) is a common mental health disorder of childhood and adolescence. CD’s complexity, with its heterogenous clinical manifestations and overlapping comorbidities makes the application of evidence-based management approaches challenging. This article aims to combine a systematic review of the available literature, with a consensus opinion from both child and adolescent psychiatrists and developmental pediatricians on the clinical and pharmacological management of children and adolescents with conduct disorder (CD). Areas covered: The authors review the CD population and provide a systematic review and meta-analysis of the effectiveness and safety of pharmacotherapies using preferred reporting items for systematic review and meta-analysis (PRISMA) and strength of evidence recommendation taxonomy (SORT) guidelines. The authors then provide an expert clinical opinion for the use of different pharmacotherapies to address aggressive and disruptive behavior in children. Expert opinion: Atypical antipsychotics (e.g. risperidone) demonstrate evidence for efficacy in CD. Other pharmacotherapies (e.g. mood stabilizers, anticonvulsants, psychostimulants and selective norepinephrine reuptake inhibitors) have a low level of evidence for CD alone, however, can sometimes be effective in managing the symptoms of CD when other psychiatric disorders are also present.",
author = "Sohil Khan and John Down and Nisreen Aouira and William Bor and Alison Haywood and Robyn Littlewood and Helen Heussler and Brett McDermott",
year = "2019",
month = "3",
day = "24",
doi = "10.1080/14656566.2018.1561862",
language = "English",
volume = "20",
pages = "571--583",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "5",

}

Khan, S, Down, J, Aouira, N, Bor, W, Haywood, A, Littlewood, R, Heussler, H & McDermott, B 2019, 'Current pharmacotherapy options for conduct disorders in adolescents and children', Expert Opinion on Pharmacotherapy, vol. 20, no. 5, pp. 571-583. https://doi.org/10.1080/14656566.2018.1561862

Current pharmacotherapy options for conduct disorders in adolescents and children. / Khan, Sohil; Down, John; Aouira, Nisreen; Bor, William; Haywood, Alison; Littlewood, Robyn; Heussler, Helen; McDermott, Brett.

In: Expert Opinion on Pharmacotherapy, Vol. 20, No. 5, 24.03.2019, p. 571-583.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current pharmacotherapy options for conduct disorders in adolescents and children

AU - Khan, Sohil

AU - Down, John

AU - Aouira, Nisreen

AU - Bor, William

AU - Haywood, Alison

AU - Littlewood, Robyn

AU - Heussler, Helen

AU - McDermott, Brett

PY - 2019/3/24

Y1 - 2019/3/24

N2 - Introduction: Conduct disorder (CD) is a common mental health disorder of childhood and adolescence. CD’s complexity, with its heterogenous clinical manifestations and overlapping comorbidities makes the application of evidence-based management approaches challenging. This article aims to combine a systematic review of the available literature, with a consensus opinion from both child and adolescent psychiatrists and developmental pediatricians on the clinical and pharmacological management of children and adolescents with conduct disorder (CD). Areas covered: The authors review the CD population and provide a systematic review and meta-analysis of the effectiveness and safety of pharmacotherapies using preferred reporting items for systematic review and meta-analysis (PRISMA) and strength of evidence recommendation taxonomy (SORT) guidelines. The authors then provide an expert clinical opinion for the use of different pharmacotherapies to address aggressive and disruptive behavior in children. Expert opinion: Atypical antipsychotics (e.g. risperidone) demonstrate evidence for efficacy in CD. Other pharmacotherapies (e.g. mood stabilizers, anticonvulsants, psychostimulants and selective norepinephrine reuptake inhibitors) have a low level of evidence for CD alone, however, can sometimes be effective in managing the symptoms of CD when other psychiatric disorders are also present.

AB - Introduction: Conduct disorder (CD) is a common mental health disorder of childhood and adolescence. CD’s complexity, with its heterogenous clinical manifestations and overlapping comorbidities makes the application of evidence-based management approaches challenging. This article aims to combine a systematic review of the available literature, with a consensus opinion from both child and adolescent psychiatrists and developmental pediatricians on the clinical and pharmacological management of children and adolescents with conduct disorder (CD). Areas covered: The authors review the CD population and provide a systematic review and meta-analysis of the effectiveness and safety of pharmacotherapies using preferred reporting items for systematic review and meta-analysis (PRISMA) and strength of evidence recommendation taxonomy (SORT) guidelines. The authors then provide an expert clinical opinion for the use of different pharmacotherapies to address aggressive and disruptive behavior in children. Expert opinion: Atypical antipsychotics (e.g. risperidone) demonstrate evidence for efficacy in CD. Other pharmacotherapies (e.g. mood stabilizers, anticonvulsants, psychostimulants and selective norepinephrine reuptake inhibitors) have a low level of evidence for CD alone, however, can sometimes be effective in managing the symptoms of CD when other psychiatric disorders are also present.

UR - http://www.scopus.com/inward/record.url?scp=85063139960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063139960&partnerID=8YFLogxK

U2 - 10.1080/14656566.2018.1561862

DO - 10.1080/14656566.2018.1561862

M3 - Review article

C2 - 30702354

AN - SCOPUS:85063139960

VL - 20

SP - 571

EP - 583

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 5

ER -